139 related articles for article (PubMed ID: 34699259)
1. Pharmacogenomics for Clinical Trials of COVID-19 Medicines: Why Is This Important Now?
Şardaş S; Özdemir V
OMICS; 2021 Nov; 25(11):679-680. PubMed ID: 34699259
[No Abstract] [Full Text] [Related]
2. Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians.
Liuzzo G; Patrono C
Eur Heart J; 2021 Mar; 42(9):882-883. PubMed ID: 33569601
[No Abstract] [Full Text] [Related]
3. Potential drug development and therapeutic approaches for clinical intervention in COVID-19.
Dowarah J; Marak BN; Yadav UCS; Singh VP
Bioorg Chem; 2021 Sep; 114():105016. PubMed ID: 34144277
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?
Alany RG
Pharm Dev Technol; 2020 Jul; 25(6):649. PubMed ID: 32423342
[No Abstract] [Full Text] [Related]
5. Recent Approaches of Repositioning and Traditional Drugs for the Treatment of COVID-19 Pandemic Outbreak.
Tandon N; Luxami V; Tandon R; Paul K
Mini Rev Med Chem; 2021; 21(8):952-968. PubMed ID: 33234101
[TBL] [Abstract][Full Text] [Related]
6. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
Goel B; Bhardwaj N; Tripathi N; Jain SK
Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 Pharmacotherapy: Drug Development, Repurposing of Drugs, and the Role of Pharmacogenomics.
Bock R; Babayeva M; Loewy ZG
Methods Mol Biol; 2022; 2547():187-199. PubMed ID: 36068465
[TBL] [Abstract][Full Text] [Related]
8. Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
Akilesh SM; J R; Palanisamy D; Wadhwani A
Curr Pharm Biotechnol; 2021; 22(2):192-199. PubMed ID: 32867651
[TBL] [Abstract][Full Text] [Related]
9. Drug researchers pursue new lines of attack against COVID-19.
Harrison C
Nat Biotechnol; 2020 Jun; 38(6):659-662. PubMed ID: 32417850
[No Abstract] [Full Text] [Related]
10. Personalized therapy: can it tame the COVID-19 monster?
Arish M; Naz F
Per Med; 2021 Sep; 18(6):583-593. PubMed ID: 34649460
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs.
Badary OA
Pharmacogenomics J; 2021 Jun; 21(3):275-284. PubMed ID: 33542445
[TBL] [Abstract][Full Text] [Related]
12. Can we use hydroxychloroquine to treat COVID-19 now?
Chen J; Liu D; Yin L; Zhang L; Lu H
Int J Antimicrob Agents; 2021 Jan; 57(1):106173. PubMed ID: 33408016
[No Abstract] [Full Text] [Related]
13. COVID-19 trials in Italy: A call for simplicity, top standards and global pooling.
Maggioni AP; Andreotti F; Gervasoni C; Di Pasquale G
Int J Cardiol; 2020 Nov; 318():160-164. PubMed ID: 32610153
[TBL] [Abstract][Full Text] [Related]
14. Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.
Paul SS; Biswas G
Mini Rev Med Chem; 2021; 21(9):1123-1143. PubMed ID: 33355053
[TBL] [Abstract][Full Text] [Related]
15. Advanced statistical methods and designs for clinical trials for COVID-19.
Shan G; Wang W
Int J Antimicrob Agents; 2021 Jan; 57(1):106167. PubMed ID: 33408032
[No Abstract] [Full Text] [Related]
16. Repurposing antimalarials and other drugs for COVID-19.
Schlagenhauf P; Grobusch MP; Maier JD; Gautret P
Travel Med Infect Dis; 2020; 34():101658. PubMed ID: 32247925
[No Abstract] [Full Text] [Related]
17. COVID-19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates.
Ulm JW; Nelson SF
Transbound Emerg Dis; 2021 Mar; 68(2):313-317. PubMed ID: 32619318
[TBL] [Abstract][Full Text] [Related]
18. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
Wang S; Sun Q; Xu Y; Pei J; Lai L
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143
[TBL] [Abstract][Full Text] [Related]
19. Repurposing drugs during the COVID-19 pandemic and beyond.
Ravi S; Jadhav S; Vaidya A; Ghooi R
Pharm Pat Anal; 2021 Jan; 10(1):9-12. PubMed ID: 33445955
[No Abstract] [Full Text] [Related]
20. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing.
Das AB
BMC Med Genomics; 2021 Sep; 14(1):226. PubMed ID: 34535131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
